BMRA vs. OCX, AWH, TRIB, CDIO, ICCC, NYMX, MYMD, VBIV, SNCE, and IMPL
Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include OncoCyte (OCX), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), ImmuCell (ICCC), Nymox Pharmaceutical (NYMX), MyMD Pharmaceuticals (MYMD), VBI Vaccines (VBIV), Science 37 (SNCE), and Impel Pharmaceuticals (IMPL). These companies are all part of the "medical" sector.
Biomerica vs.
Biomerica (NASDAQ:BMRA) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
Biomerica has a beta of -0.62, indicating that its share price is 162% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
In the previous week, Biomerica and Biomerica both had 1 articles in the media. Biomerica's average media sentiment score of 1.00 beat OncoCyte's score of 0.63 indicating that Biomerica is being referred to more favorably in the media.
Biomerica received 136 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 12.50% of users gave OncoCyte an outperform vote.
22.0% of Biomerica shares are owned by institutional investors. Comparatively, 81.2% of OncoCyte shares are owned by institutional investors. 15.7% of Biomerica shares are owned by company insiders. Comparatively, 6.7% of OncoCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
OncoCyte has a consensus target price of $1.11, suggesting a potential upside of 388.58%. Given OncoCyte's higher probable upside, analysts plainly believe OncoCyte is more favorable than Biomerica.
Biomerica has a net margin of -74.56% compared to OncoCyte's net margin of -787.97%. OncoCyte's return on equity of -34.08% beat Biomerica's return on equity.
Biomerica has higher revenue and earnings than OncoCyte.
Summary
Biomerica and OncoCyte tied by winning 7 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Biomerica Competitors List
Related Companies and Tools